Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostate Cancer Metastatic × Hydrocortisone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Leukemia 8 Prostatic Neoplasms 6 Lymphoma 5 Burkitt Lymphoma 3 Anemia, Refractory, with Excess of Blasts 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Myelodysplastic Syndromes 2 Lymphoma, Large-Cell, Anaplastic 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Biphenotypic, Acute 2 Anemia, Refractory 2 Prostate Cancer Metastatic 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lipomatosis, Multiple Symmetrical 1 Lipoma 1 Leukemia, Myelomonocytic, Juvenile 1 Leukemia, Myeloid, Acute 1 Drug-Related Side Effects and Adverse Reactions 1 Dendritic Cell Sarcoma, Interdigitating 1 Cardiotoxicity 1

Interventions

enzalutamide 2 cabazitaxel 2 Prednisone 2 Androgen Antagonists 2 fludrocortisone acetate 1 darolutamide 1 XRP6258 1 Radiosurgery 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 Hydrocortisone 1 Granulocyte Colony-Stimulating Factor 1 Docetaxel 1 Dexamethasone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06136624 2026-03-11

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡